$1.45
+0.04 (+2.84%)
Open$1.36
Previous Close$1.41
Day High$1.52
Day Low$1.35
52W High$4.45
52W Low$1.22
Volume—
Avg Volume59.9K
Market Cap35.05M
P/E Ratio—
EPS$-1.14
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,777.2% upside
Current
$1.45
$1.45
Target
$27.22
$27.22
$16.99
$27.22 avg
$37.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 325.1K | 199.4K | 4.38M |
| Net Income | -47,813,852 | -26,395,428 | -1,275,702 |
| Profit Margin | -14,755.4% | -14,017.6% | -29.1% |
| EBITDA | -57,892,760 | -33,734,970 | -1,970,058 |
| Free Cash Flow | — | — | -1,043,157 |
| Rev Growth | +63.0% | +63.0% | +7.3% |
| Debt/Equity | — | — | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |